Major Distribution Agreement

Provexis PLC
09 January 2006


9 January 2006

                                  PROVEXIS PLC
                         ('Provexis' or the 'Company')

                Further Major Distribution Agreement for SircoTM

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a further distribution agreement with a
market leading supermarket chain for its SircoTM heart health juice drink.

From February 2006, SircoTM Blueberry & Apple variety will be stocked in
approximately 200 of this supermarket's key premier stores bringing the total UK
distribution base for SircoTM to over 500 stores by the end of February 2006.

Further to the Company's announcement released on 16 December 2005, SircoTM is
now available in 211 Sainsbury's stores and is expected to be available in 100
stores of the second multiple supermarket chain from 23 January 2006.

SircoTM is the first heart health product to contain the patented FruitflowTM
technology. FruitflowTM was developed by Provexis in order to help regular
'healthy' consumers reduce the risk of heart attack and stroke. The natural
bioactive works by reducing blood platelet aggregation ('thinning the blood'), 
a significant contributing factor to a thrombosis (internal blood clot). SircoTM
carries the health claim 'Helps to Maintain a Healthy Heart and Benefits
Circulation' and is approved by the leading heart health charity, HEART UK.

Commenting on the expanded distribution, Dr Stephen Franklin, CEO of Provexis,
said:

'We are delighted to have secured a listing with a third major retailer. The
distribution base of SircoTM is expanding on schedule and will be sufficiently
established to maximise the nationwide, multimedia, advertising campaign which
will run throughout the Spring and early Summer'.

For further information please contact:

Provexis plc
Dr Stephen Franklin                               020 8392 6631

Bell Pottinger Corporate & Financial
Ann-Marie Wilkinson/Emma Kent                     020 7861 3232



                      This information is provided by RNS
            The company news service from the London Stock Exchange